Poly Medicure Ltd
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]
- Market Cap ₹ 18,808 Cr.
- Current Price ₹ 1,854
- High / Low ₹ 3,358 / 1,821
- Stock P/E 52.6
- Book Value ₹ 273
- Dividend Yield 0.19 %
- ROCE 20.1 %
- ROE 15.8 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 28.4% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
322 | 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,669 | 1,688 | |
246 | 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,014 | 1,214 | 1,233 | |
Operating Profit | 76 | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 361 | 455 | 455 |
OPM % | 24% | 22% | 21% | 21% | 23% | 22% | 24% | 28% | 23% | 24% | 26% | 27% | 27% |
11 | 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 94 | 120 | |
Interest | 9 | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 14 | 12 |
Depreciation | 14 | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 63 | 83 | 87 |
Profit before tax | 63 | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 453 | 477 |
Tax % | 30% | 27% | 27% | 27% | 27% | 35% | 24% | 25% | 25% | 25% | 25% | 25% | |
45 | 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 358 | |
EPS in Rs | 5.11 | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 | 26.91 | 33.41 | 35.29 |
Dividend Payout % | 20% | 18% | 27% | 40% | 25% | 27% | 18% | 18% | 16% | 16% | 11% | 10% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 19% |
3 Years: | 22% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 28% |
3 Years: | 33% |
TTM: | 33% |
Stock Price CAGR | |
---|---|
10 Years: | 25% |
5 Years: | 31% |
3 Years: | 22% |
1 Year: | -20% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 16% |
3 Years: | 16% |
Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 |
Reserves | 124 | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 |
67 | 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 180 | |
73 | 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 215 | 246 | |
Total Liabilities | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 |
123 | 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | |
CWIP | 20 | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 |
Investments | 3 | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 132 | 167 | 1,077 |
140 | 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 732 | 748 | 930 | |
Total Assets | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
66 | 63 | 63 | 56 | 75 | 106 | 128 | 119 | 123 | 191 | 266 | 240 | |
-58 | -59 | -31 | -56 | -88 | -101 | -107 | -436 | -85 | -179 | -241 | -1,194 | |
5 | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 | |
Net Cash Flow | 13 | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 52 | 59 | 74 | 77 | 79 | 77 | 68 | 72 | 82 | 77 | 72 | 76 |
Inventory Days | 142 | 148 | 114 | 194 | 161 | 186 | 241 | 217 | 218 | 237 | 205 | 233 |
Days Payable | 101 | 101 | 76 | 131 | 96 | 123 | 142 | 111 | 115 | 105 | 89 | 71 |
Cash Conversion Cycle | 94 | 106 | 111 | 140 | 144 | 139 | 166 | 179 | 185 | 209 | 188 | 239 |
Working Capital Days | 20 | 25 | 35 | 55 | 71 | 56 | 44 | 74 | 81 | 69 | 54 | 74 |
ROCE % | 33% | 30% | 26% | 24% | 26% | 22% | 25% | 22% | 17% | 18% | 24% | 20% |
Documents
Announcements
- Transcript Of Investors/Analysts Conference Call Held On 25Th September, 2025. 1 Oct
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
27 Sep - 30th AGM (25 Sep 2025): all resolutions passed; borrowing limit hiked from Rs400Cr to Rs1000Cr; dividend approved; Pankaj Gupta appointed.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
25 Sep - Posted Sep 25, 2025 analyst call audio on Citieffe Group acquisition, link provided.
-
Closure of Trading Window
25 Sep - Trading window closed Oct 1, 2025 until 48 hours after results for quarter/half-year ended Sep 30, 2025.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
25 Sep - 25 Sep 2025 AGM: propose increase borrowing limit ₹400Cr→₹1,000Cr; dividend; director reappointments; charges creation.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Concalls
-
Oct 2025Transcript PPT
-
Sep 2025Transcript PPT
-
Sep 2025Transcript PPT REC
-
Aug 2025TranscriptNotesPPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024TranscriptPPTREC
-
Sep 2024TranscriptNotesPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
Product Portfolio
It is a medical devices company with a product portfolio comprised of 200+ SKUs of medical devices across 12 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. [1]